Patents by Inventor Josbert Maarten Metselaar
Josbert Maarten Metselaar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230293432Abstract: The invention relates to a polymeric micelle comprising a block copolymer comprising a polyethylene glycol (PEG) hydrophilic block and a hydrophobic block, and a compound according to formula (I) or formula (III) encapsulated within said polymeric micelle and to uses thereof.Type: ApplicationFiled: July 6, 2021Publication date: September 21, 2023Inventors: Yang SHI, Twan LAMMERS, Josbert Maarten METSELAAR
-
Publication number: 20200253871Abstract: The invention relates to a pharmaceutical composition comprising liposomes composed of non-charged vesicle-forming lipids, optionally including not more than 10 mole percent of negatively charged vesicle-forming lipids and/or not more than 10 mole percent of PEGylated lipids, the liposomes having a selected mean particle diameter in the size range of 40-200 nm and comprising a first corticosteroid in water soluble form, for the site-specific treatment of inflammatory disorders in humans, providing in human patients a fast, strong, and durable anti-inflammatory effect for at least 2 weeks at a dose of at most 5 mg/kg body weight of prednisolone or an equipotent dose corticosteroid other than prednisolone at a treatment frequency of at most once per two weeks.Type: ApplicationFiled: November 11, 2019Publication date: August 13, 2020Applicant: LAURENTIA HOLDING B.V.Inventor: Josbert Maarten METSELAAR
-
Patent number: 10471010Abstract: The invention relates to a pharmaceutical composition comprising liposomes composed of non-charged vesicle-forming lipids, optionally including not more than 10 mole percent of negatively charged vesicle-forming lipids and/or not more than 10 mole percent of PEGylated lipids, the liposomes having a selected mean particle diameter in the size range of 40-200 nm and comprising a first corticosteroid in water soluble form, for the site-specific treatment of inflammatory disorders in humans, providing in human patients a fast, strong, and durable anti-inflammatory effect for at least 2 weeks at a dose of at most 5 mg/kg body weight of prednisolone or an equipotent dose corticosteroid other than prednisolone at a treatment frequency of at most once per two weeks.Type: GrantFiled: November 2, 2012Date of Patent: November 12, 2019Assignee: ENCELADUS PHARMACEUTICALS B.V.Inventor: Josbert Maarten Metselaar
-
Publication number: 20190151236Abstract: The invention relates to topical injection in inflamed lesions or areas with liposomal corticosteroids.Type: ApplicationFiled: April 28, 2017Publication date: May 23, 2019Applicants: Enceladus Pharmaceuticals B.V., Universiteit Utrechat Holding B.V., Singapore Health Services PTE. LTD.Inventors: Josbert Maarten METSELAAR, Chee Wai WONG, Bertrand Marcel Stanislas CZARNY, Tina Tzee Ling WONG
-
Publication number: 20180289809Abstract: A formulation includes a continuous hydrophobic phase, a hydrophilic phase, at least one hydrophilic compound substantially dissolved in the hydrophilic phase, and a stabilizing component. The stabilizing component can contain D-a-tocopheryl polyethylene glycol 1000 succinate (TPGS) and/or at least one emulsifier having a hydrophilic-lipophilic balance (HLB) value of at least 10. In one alternative, the stabilizing component contains a first, polysorbate emulsifier having an HLB value of at least 10, and a second emulsifier having an HLB value of less than 10.Type: ApplicationFiled: January 22, 2016Publication date: October 11, 2018Inventors: Chantal Burnison, Josbert Maarten Metselaar, Chirstopher Stahl
-
Publication number: 20150050329Abstract: The invention relates to a pharmaceutical composition comprising liposomes composed of non-charged vesicle-forming lipids, optionally including not more than 10 mole percent of negatively charged vesicle-forming lipids and/or not more than 10 mole percent of PEGylated lipids, the liposomes having a selected mean particle diameter in the size range of 40-200 nm and comprising a first corticosteroid in water soluble form, for the site-specific treatment of inflammatory disorders in humans, providing in human patients a fast, strong, and durable anti-inflammatory effect for at least 2 weeks at a dose of at most 5 mg/kg body weight of prednisolone or an equipotent dose corticosteroid other than prednisolone at a treatment frequency of at most once per two weeks.Type: ApplicationFiled: November 2, 2012Publication date: February 19, 2015Inventor: Josbert Maarten Metselaar
-
Publication number: 20140287027Abstract: The invention relates to the use of a composition comprising a corticosteroid encapsulated in a vesicle for the manufacture of a medicament for treating cancer, such as the use of a composition comprising a corticosteroid and liposomes, the liposomes comprising a non-charged vesicle-forming lipid, and optionally an amphipathic vesicle-forming lipid and/or a negatively charged vesicle-forming lipid. The invention further relates to a new pharmaceutical composition suitable for treating cancer, and especially solid primary and secondary tumors.Type: ApplicationFiled: May 28, 2014Publication date: September 25, 2014Applicant: Enceladus Pharmaceuticals B.V.Inventors: Raymond Michel Schiffelers, Josbert Maarten Metselaar, Grietje Molema, Gerrit Storm
-
Publication number: 20140255474Abstract: A pharmaceutical composition for parenteral administration, comprising liposomes composed of non-charged vesicle-forming lipids, optionally including not more than five (5) mole percent of charged vesicle-forming lipids, the liposomes having a selected mean particle diameter in the size range between about 40-200 nm and containing a water soluble corticosteroid for the site-specific treatment of inflammatory disorders, is provided.Type: ApplicationFiled: May 27, 2014Publication date: September 11, 2014Applicant: Enceladus Pharmaceuticals B.V.Inventor: Josbert Maarten Metselaar
-
Patent number: 7955618Abstract: A pharmaceutical composition for parenteral administration, comprising liposomes composed of non-charged vesicle-forming lipids, including up to 20 mole percent of an amphipathic vesicle-forming lipid derivatized with polyethyleneglycol, and optionally including not more than 10 mole percent of negatively charged vesicle-forming lipids, the liposomes having a selected mean particle diameter in the size range between about 40-200 nm and containing a water soluble corticosteroid for the site-specific treatment of inflammatory disorders, is provided.Type: GrantFiled: June 5, 2003Date of Patent: June 7, 2011Assignee: Enceladus Pharmaceuticals B.V.Inventors: Josbert Maarten Metselaar, Marca Henriette M. Wauben, Gerrit Storm
-
Publication number: 20100145018Abstract: Lipid conjugates of a poly-(amino acid), a poly-(amino acid derivative) or a poly-(amino acid analogue), such as poly-[N-(2-hydroxyethyl)-glutamine](PHEG), are provided.Type: ApplicationFiled: July 6, 2009Publication date: June 10, 2010Applicant: Astellas Pharma Europe BVInventors: Josbert Maarten Metselaar, Wilhelmus Everardus Hennick, Tom De Vringer, Leonardus Wilhelmus Theodorus De Boer, Christien Oussoren, Gerrit Storm, Peter Bruin
-
Publication number: 20100143452Abstract: The present invention relates to liposomal compositions comprising polyphenol in the interior of a colloidal carrier, and especially to the use of such compositions in the treatment of cancer or in the inhibition of cancer growth and in the treatment of inflammatory and autoimmune conditions. More specifically, the invention relates to a method for targeting a polyphenol to tumor tissue, or to sites in the body requiring anti-inflammatory activity or activity against autoimmune conditions. Furthermore, the present invention describes a method of post-loading a polyphenol derivate such as caffeic acid into a liposome.Type: ApplicationFiled: December 11, 2007Publication date: June 10, 2010Applicant: Universiteit Utrecht Holding B.V.Inventors: Raymond Michel Schiffelers, Josbert Maarten Metselaar, Gerrit Storm
-
Publication number: 20100143453Abstract: The present invention relates to compositions comprising non-steroidal anti-inflammatory compounds, and especially to the use of such compositions in the treatment of cancer or in the inhibition of cancer growth. More specifically, the invention relates to a method for targeting an anti-inflammatory compound to tumor tissue.Type: ApplicationFiled: December 11, 2007Publication date: June 10, 2010Inventors: Raymond Michel Schiffelers, Josbert Maarten Metselaar, Gerrit Storm
-
Publication number: 20090226509Abstract: A pharmaceutical composition for parenteral administration, comprising liposomes composed of non-charged vesicle-forming lipids, optionally including not more than five (5) mole percent of charged vesicle-forming lipids, the liposomes having a selected mean particle diameter in the size range between about 40-200 nm and containing a water soluble corticosteroid for the site-specific treatment of inflammatory disorders, is provided.Type: ApplicationFiled: May 5, 2009Publication date: September 10, 2009Applicant: Enceladus Pharmaceuticals B.V.Inventor: Josbert Maarten Metselaar
-
Publication number: 20040254352Abstract: Lipid conjugates of a poly-(amino acid), a poly-(amino acid derivative) or a poly-(amino acid analogue), such as poly-[N-(2-hydroxyethyl)-glutamine](PHEG), are provided.Type: ApplicationFiled: July 23, 2004Publication date: December 16, 2004Inventors: Josbert Maarten Metselaar, Wilhelmus Everardus Hennick, Tom De Vringer, Leonardus Wilhelmus Theodorus De Boer, Christien Oussoren, Gerrit Storm, Peter Bruin
-
Publication number: 20040241222Abstract: Colloidal carrier compositions, comprising an active agent and a lipid conjugate of a poly-(amino acid), a poly-(amino acid derivative) or poly-(amino acid analogue), such as poly-[N-(2-hydroxyethyl)-glutamine] (PHEG), are provided.Type: ApplicationFiled: June 17, 2004Publication date: December 2, 2004Inventors: Josbert Maarten Metselaar, Wilhelmus Evardus Hennick, Tom De Vringer, Leonardus Wilhelmus Theodorus De Boer, Christien Oussoren, Gerrit Storm, Peter Bruin
-
Publication number: 20040037875Abstract: A pharmaceutical composition for parenteral administration, comprising liposomes composed of non-charged vesicle-forming lipids, including up to 20 mole percent of an amphipathic vesicle-forming lipid derivatized with polyethyleneglycol, and optionally including not more than 10 mole percent of negatively charged vesicle-forming lipids, the liposomes having a selected mean particle diameter in the size range between about 40-200 nm and containing a water soluble corticosteroid for the site-specific treatment of inflammatory disorders, is provided.Type: ApplicationFiled: June 5, 2003Publication date: February 26, 2004Inventors: Josbert Maarten Metselaar, Marca Henriette M. Wauben, Gerrit Storm